Imagerie d’un néo-vaisseau choroïdien compliquant une maladie de Best traité par injection intravitréenne de bévacizumab

Eid, L.; Coste-Verdier, V.; Rougier, M.–B.; Delyfer, Marie-Noëlle; Korobelnik, J.-F.

doi:10.1016/j.jfo.2018.11.023

Cited by 1 publication

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Choroidal neovascularization complicating BVMD generally requires a reduced number of antiangiogenic injections compared to other macular dystrophies [8] associated to an improvement of the visual function without recurrence in most cases, [9] highlighting relatively non-aggressive character of this CNV. Observation findings by Leu et al [10] and Cakir et al [8] reported both morphological and functional gains after one single intravitreous injection of bevacizumab and bevacizumab-triamcinolone respectively.…”

Section: Discussionmentioning

confidence: 99%

Intra-Vitreous Injections of Bevacizumab in Choroidal Neovascularization Complicating Best Vitelliform Macular Dystrophy: Case Report of a Child

Elkhoyaali¹,

Jeddou²,

Zerrouk³

et al. 2021

austinjclincaserep

View full text Add to dashboard Cite

A 15-year-old child followed for Best vitelliform macular dystrophy presented to the clinic with an abrupt visual impairment of his left eye. Fundus examination showed bilateral vitelliform lesions, with serous retinal detachment and adjacent retinal hemorrhage in the left eye. Fluorescein angiography and optical coherence tomography confirmed the diagnosis of type-2 choroidal neovascularization complicating the Best disease. The juxtafoveal location of the choroidal neovascularization prompted us to realize monthly intra-vitreous injections of bevacizumab. After the fourth injection, we observed visual and anatomical improvement that remained stable after a 12-month follow-up. It’s important to look for complications in front of a sudden decrease in visual acuity in Best disease.

show abstract

Section: Discussionmentioning

confidence: 99%